

Results of 2025 Annual General Meeting

Melbourne, Australia; 14 November 2025: Starpharma (ASX: SPL, US OTC: SPHRY) today announces the details of the resolutions and the proxies and votes received in respect of each resolution at its Annual General Meeting (AGM), held today in accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act, as set out in the appended proxy and voting summary.

About Starpharma

Starpharma ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology.

Dendrimers are precise, synthetically manufactured, nanoscale molecules. Their unique properties—including their size, structure, high degree of branching, polyvalency, and water solubility—are advantageous in medical and pharmaceutical applications.

Starpharma's portfolio of dendrimer-based products includes three clinical-stage DEP® (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products.

For more information about Starpharma, visit www.starpharma.com or connect with Starpharma on [LinkedIn](#).

Investor & Media Relations

Gabriella Hold

gaby@thecapitalnetwork.com.au

Starpharma Holdings Limited

Cheryl Maley, Chief Executive Officer

Justin Cahill, Chief Financial and Operations
Officer and Company Secretary

+61 3 8532 2704

investor.relations@starpharma.com

4-6 Southampton Crescent

Abbotsford VIC 3067

Disclosure

This ASX Announcement was authorised for release by the Chair, Mr Rob Thomas.

Forward-Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document, nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of Remuneration Report	Ordinary	161,924,509 98.36%	1,768,068 1.07%	934,638 0.57%	234,294	167,816,466 98.96%	1,768,068 1.04%	634,295	Carried
2 Re-election of Board endorsed Director, Dr Jeff Davies	Ordinary	166,790,585 98.86%	1,000,058 0.59%	939,438 0.55%	73,411	173,186,920 99.43%	1,000,058 0.57%	148,834	Carried
3 Approval of issue of Performance Rights to Ms Cheryl Maley	Ordinary	161,650,939 98.12%	2,156,950 1.31%	938,638 0.57%	239,982	167,946,897 98.73%	2,156,950 1.27%	414,982	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.